Cellexus research, develop and manufacture the CellMaker range of revolutionary single-use, airlift bioreactor systems and related technology.

The most innovative airlift technology on the market, the CellMaker system offers a reduced investment alternative to existing technologies with a combined low footprint and excellent performance. The CellMaker bioreactors are available in 8L and 50L and the option of fitted sensors for pH and dissolved oxygen to enhance process control, maximise yields and reduce time to market. The CellMaker range is designed to be versatile and has been proven in a wide range of cell lines (E Coli, Pichia, Bacteriophage, Yeast, Algae) for fermentation applications used in the life sciences and biopharmaceutical industries. We enable our customers to accelerate their processes and increase their yields when compared to standard methods.

Workshop and demo

Cellexus are delighted to present the CellMaker Low Flow bioreactor system in this workshop. We will demonstrate the system on-site and detail some of the exciting results already being achieved by our clients.

The CellMaker Low Flow single-use, airlift bioreactor system is specially designed to improve mammalian cell culture. Our innovative airlift technology allows for gentle yet efficient mixing, while our single-use bioreactor bags eliminate cross-contamination. Our system is self-contained, with no mechanical moving parts, offering extremely low shear stress.

Cellexus also offer a Regular, Dual Regular and Plus CellMaker systems, designed for a range of cell culture and fermentation requirements, in working volumes from 3L to 50L.

Find out more about Cellexus and the CellMaker on our website: Cellexus

Miltenyi Biotec is a global provider of products and services that advance biomedical research and cellular therapy. Our innovative tools support research at every level, from basic research to translational research to clinical application. Used by scientists and clinicians around the world, our technologies cover techniques of sample preparation, cell isolation, cell sorting, flow cytometry, and cell culture. Our 30 years of expertise spans research areas including immunology, stem cell biology, neuroscience, and cancer. Today, Miltenyi Biotec has about 3,000 employees in 28 countries – all dedicated to helping researchers and clinicians make a greater impact on science and health.

Automated manufacturing of adherent cells is a technical challenge. Adherent cells require large cultureware surfaces and periodic passaging procedures to realize cell manufacturing at desired qualities and scales. In addition, some cell types may require pre-coated cultureware to which they can attach to.

Workshop and demo

During the workshop we will demo our latest application: The CliniMACS Prodigy Adherent Cell Culture System, a cell manufacturing process on the CliniMACS Prodigy Platform. The CliniMACS Prodigy Adherent Cell Culture System allows for GMP-compliant and scalable manufacturing of different adherent cell types, such as PSCs, their derivatives, and MSCs.

Miltenyi Biotec

VivaBioCell develops, manufactures and commercializes automated solutions for the manufacturing of advanced therapy medicinal products, for both research and clinical applications. VivaBioCell is part of NantWorks LLC group (Culver City, California) which supports an ecosystem of companies focused on the development and commercialization of innovative therapies, operating at the intersection of research, infrastructure and market. VivaBioCell’s mission is to provide smart and cost-effective solutions that allow for the improvement and standardization of advanced therapies manufacturing. VivaBioCell technology, together with the strong commitment in supporting the customers during all phases of set-up and validation, allow for a safe seamless conversion of a manual protocol into a high-standardized scalable process, drawing the attention on risk reduction and cost containment, while maintaining regulatory and quality requirements. Indeed, VivaBioCell truly wants to inspire the application and diffusion of sustainable advanced therapies, with the long-term vision of bridging regenerative medicine into the mainstream worldwide clinical practice.

Workshop

VivaBioCell will present the NANT 001 and NANT XL automated systems for cell expansion, functionally closed bioreactors designed to overcome the challenges of GMP-compliant manufacturing of ATMPs. These systems, able to expand both cells in adhesion and suspension, are currently being used for the manufacturing of cell-therapy products in the context of clinical trials both in Europe and U.S.A.

VivaBioCell